Oxprenolol
From Wikipedia, the free encyclopedia
 |
|
|
Oxprenolol
|
|
| Systematic (IUPAC) name | |
| 1-propan-2-ylamino-3-(2 -prop-2-enoxyphenoxy)-propan-2-ol |
|
| Identifiers | |
| CAS number | 6452-71-7 |
| ATC code | C07AA02 |
| PubChem | 4631 |
| Chemical data | |
| Formula | C15H23NO3 |
| Mol. weight | 265.348 |
| Pharmacokinetic data | |
| Bioavailability | 20-70% |
| Metabolism | Hepatic |
| Half life | 1-2hours |
| Excretion | Renal Lactic (In lactiferous females) |
| Therapeutic considerations | |
| Pregnancy cat. |
C(AU) |
| Legal status |
℞ Prescription only |
| Routes | oral |
Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris and abnormal heart rhythms. It is also used for treating high blood pressure.
Oxprenolol is a lipophilic beta blocker which passes the blood-brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol. (McDevitt 1987)
[edit] References
- McDevitt DG. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J. 1987 Dec;8 Suppl M:9-14. Review. PMID 2897304.
| Beta blockers (C07) edit | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
